Pelthos Therapeutics Reports Strong Q2 2026 Growth on Zelsuvmi Momentum
Event summary
- Zelsuvmi net product revenue grew 45% to $15.4 million in Q2 2026, up from $10.7 million in Q1 2026.
- Units dispensed increased by 48% quarter-over-quarter, with over 30,000 units dispensed since launch.
- Pelthos accessed an additional $10.0 million under the Horizon facility based on trailing twelve-month net product revenues of $42.3 million.
- Net loss for Q2 2026 was $(23.4) million, compared to $(25.1) million in Q1 2026.
The big picture
Pelthos Therapeutics is leveraging the success of its lead product, Zelsuvmi, to drive significant revenue growth in a competitive biopharmaceutical landscape. The company's ability to secure additional financing and expand its product portfolio positions it for further market penetration. However, sustaining this momentum will depend on successful commercialization of upcoming products and maintaining strong prescriber adoption.
What we're watching
- Product Pipeline
- The planned commercialization of Xepi in Q1 2027 and Xeglyze in Q3 2027 will be critical to sustaining growth momentum.
- Financial Flexibility
- Access to additional funds under the Horizon facility will provide capital flexibility for advancing the business plan.
- Market Adoption
- The pace at which Zelsuvmi continues to gain prescriber and patient adoption will determine its long-term market penetration.
Related topics